Aarti Pharmalabs Limited (NSE: AARTIPHARM)

Market Cap	63.07B
Revenue (ttm)	19.50B
Net Income (ttm)	2.25B
Shares Out	90.61M
EPS (ttm)	24.85
PE Ratio	28.01
Forward PE	n/a
Dividend	2.00 (0.29%)
Ex-Dividend Date	Jul 31, 2024

Volume	442,828
Open	693.70
Previous Close	690.80
Day's Range	688.05 - 715.50
52-Week Range	371.10 - 721.70
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Aarti Pharmalabs

Aarti Pharmalabs Limited, together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system (CNS) agents, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medication...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Employees: 2,095
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AARTIPHARM

Financial Performance

In 2023, AARTIPHARM's revenue was 18.53 billion, a decrease of -4.76% compared to the previous year's 19.45 billion. Earnings were 2.17 billion, an increase of 12.10%.